1. Dyrskjøt L, Hansel DE, Efstathiou JA, et al. (2023): Bladder cancer. Nat Rev Dis Primers 9: 58.
2.
Sung H, Ferlay J, Siegel RL, et al. (2021): Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71: 209-249.
3.
Malats N, Real FX (2015): Epidemiology of bladder cancer. Hematol Oncol Clin North Am 29: 177-189, vii.
4.
Lobo N, Afferi L, Moschini M, et al. (2022): Epidemiology, screening, and prevention of bladder cancer. Eur Urol Oncol 5: 628-639.
5.
Richters A, Aben KKH, Kiemeney L (2020): The global burden of urinary bladder cancer: an update. World J Urol 38: 1895-1904.
6.
Xu Y, Sun G, Yang T, et al. (2024): Validation of hyperthermia as an enhancer of chemotherapeutic efficacy: insights from a bladder cancer organoid model. Int J Hyperthermia 41: 2316085.
7.
Peng Y, Mei W, Ma K, Zeng C (2021): Circulating tumor DNA and minimal residual disease (MRD) in solid tumors: current horizons and future perspectives. Front Oncol 11: 763790.
8.
Castillo RL, Ibacache M, Cortínez I, et al. (2019): dexmedetomidine improves cardiovascular and ventilatory outcomes in critically ill patients: basic and clinical approaches. Front Pharmacol 10: 1641.
9.
Kimura M, Saito S, Obata H (2012): Dexmedetomidine decreases hyperalgesia in neuropathic pain by increasing acetylcholine in the spinal cord. Neurosci Lett 529: 70-74.
10.
Che J, Liu M, Lv H (2022): Dexmedetomidine disrupts esophagus cancer tumorigenesis by modulating circ_0003340/miR-198/HMGA2 axis. Anticancer Drugs 33: 448-458.
11.
Dong J, Che J, Wu Y, et al. (2024): Dexmedetomidine promotes colorectal cancer progression via Piwil2 signaling. Cell Oncol (Dordr) 47: 1459-1474.
12.
Zhao L, Zhou X, Xie F, et al. (2022): Ferroptosis in cancer and cancer immunotherapy. Cancer Commun (Lond) 42: 88-116.
13.
Zhang C, Liu X, Jin S, et al. (2022): Ferroptosis in cancer therapy: a novel approach to reversing drug resistance. Mol Cancer 21: 47.
14.
Zhang Y, Wang X (2020): Targeting the Wnt/-catenin signaling pathway in cancer. J Hematol Oncol 13: 165.
15.
Liu MJ, Zhao XC, Gong HS, et al. (2022): Dexmedetomidine prevents hemorrhagic brain injury by reducing damage induced by ferroptosis in mice. Neurosci Lett 788: 136842.
16.
Tian H, Hou L, Xiong Y, Cheng Q (2021): Dexmedetomidine upregulates microRNA-185 to suppress ovarian cancer growth via inhibiting the SOX9/Wnt/-catenin signaling pathway. Cell Cycle 20: 765-780.
17.
Shan T, Zhou C, Yang R, et al. (2015): Lithium chloride promotes the odontoblast differentiation of hair follicle neural crest cells by activating Wnt/-catenin signaling. Cell Biol Int 39: 35-43.
18.
Gao X, Wang XL (2023): Dexmedetomidine promotes ferroptotic cell death in gastric cancer via hsa_circ_0008035/miR-302a/E2F7 axis. Kaohsiung J Med Sci 39: 390-403.
19.
Dobruch J, Oszczudłowski M (2021): Bladder cancer: Current challenges and future directions. Medicina (Kaunas) 57: 749.
20.
Shin S, Kim KJ, Hwang HJ, et al. (2021): Immunomodulatory effects of perioperative dexmedetomidine in ovarian cancer: An in vitro and xenograft mouse model study. Front Oncol 11: 722743.
21.
Jun JH, Shim JK, Oh JE, et al. (2023): Effects of dexmedetomidine on A549 non-small cell lung cancer growth in a clinically relevant surgical xenograft model. Sci Rep 13: 12471.
22.
Yu P, Zhang J, Ding Y, et al. (2022): Dexmedetomidine post-conditioning alleviates myocardial ischemia-reperfusion injury in rats by ferroptosis inhibition via SLC7A11/GPX4 axis activation. Hum Cell 35: 836-848.
23.
Ramos S, Hartenian E, Santos JC, et al. (2024): NINJ1 induces plasma membrane rupture and release of damage-associated molecular pattern molecules during ferroptosis. EMBO J 43: 1164-1186.
24.
Kim R, Hashimoto A, Markosyan N, et al. (2022): Ferroptosis of tumour neutrophils causes immune suppression in cancer. Nature 612: 338-346.
25.
Xie Q, Zhang P, Wang Y, et al. (2022): Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities. Front Oncol 12: 958720.
26.
Wan H, Xu B, Zhu N, Ren B (2020): PGC-1 activator-induced fatty acid oxidation in tumor-infiltrating CTLs enhances effects of PD-1 blockade therapy in lung cancer. Tumori 106: 55-63.
27.
Yu F, Yu C, Li F, et al. (2021): Wnt/-catenin signaling in cancers and targeted therapies. Signal Transduct Target Ther 6: 307.
28.
Jiménez-Guerrero R, Belmonte-Fernández A, Flores ML, et al. (2021): Wnt/-catenin signaling contributes to paclitaxel resistance in bladder cancer cells with cancer stem cell-like properties. Int J Mol Sci 23: 450.
29.
Li Y, Kong Y, An M, et al. (2023): ZEB1-mediated biogenesis of circNIPBL sustains the metastasis of bladder cancer via Wnt/-catenin pathway. J Exp Clin Cancer Res 42: 191.
30.
Xie J, Wang H, Xie W, et al. (2024): Gallic acid promotes ferroptosis in hepatocellular carcinoma via inactivating Wnt/-catenin signaling pathway. Naunyn Schmiedebergs Arch Pharmacol 397: 2437-2445.
31.
Wang B, Shen J, Wang Z, et al. (2018): Isomangiferin, a no-vel potent vascular endothelial growth factor receptor 2 kinase inhibitor, suppresses breast cancer growth, metastasis and angiogenesis. J Breast Cancer 21: 11-20.
